Parkinson's disease clinical research

Social Finance Announces New Career Impact Bond with Clinical Research Fastrack to Expand Access to Clinical Research Job Training, Economic Mobility

Retrieved on: 
Wednesday, July 6, 2022
Social finance, Michael & Susan Dell Foundation, Science, Research, Cancer, Industry, Parkinson's disease, Refugee, Boston, Blue Haven Initiative, The Boston Foundation, Student Bill of Rights, Parkinson's disease clinical research, Regulation D, Chronic Respiratory Disease, COVID-19, Obesity, Housing, Liver disease, Person, Investment, Degenerative disease, Information technology, Bill Ackman, Diabetes, Education, Alzheimer's disease, CEO, Greater Boston, First Ever, Combined, Partnership, Clinical research, W. K. Kellogg Foundation, Rule, Health, MacArthur Foundation, MFS Investment Management, Multimedia, View, Sepsis, Employment, Neoplasm, Michael, Entrepreneurship, Program, Arthritis, Management, Medicine, Tutoring

BOSTON and SCOTTSDALE, Ariz., July 6, 2022 /PRNewswire/ -- Today, Social Finance announced its latest Career Impact Bond, a $5 million partnership with Clinical Research Fastrack to help people facing barriers to employment, including immigrants and refugees with impressive medical or science degrees earned outside of the U.S., find careers within the growing clinical research industry.

Key Points: 
  • "We're excited to partner with Clinical Research Fastrack to train clinical research professionals who help bring new life-saving treatments to market," Social Finance CEO and Co-Founder Tracy Palandjian said.
  • "It's exciting to collaborate with Social Finance on a program that will diversify and strengthen the clinical research industry," Clinical Research Fastrack Co-Founder and CEO David Silberman said.
  • Clinical Research Fastrack was founded in 2016 to improve the quality and progress of clinical research by educating and empowering new research professionals.
  • Clinical Research Fastrack trains aspiring Clinical Research professionals and connects them with leading research organizations to elevate the efficacy of clinical trials.

The Michael J. Fox Foundation Releases New Guide, "Deep Brain Stimulation and Parkinson's -- From Decision-making to Daily Life with the Device," to Answer Questions and Encourage Conversations on Available Treatments

Retrieved on: 
Tuesday, June 15, 2021
Medicine, Clinical medicine, Branches of biology, Parkinson's disease, Aging-associated diseases, Geriatrics, Psychiatric diagnosis, Neurosurgical procedures, The Michael J. Fox Foundation, Deep brain stimulation, Shake it Up Australia Foundation, Parkinson's disease clinical research

Fox Foundation for Parkinson's Research (MJFF) today launches "Deep Brain Stimulation and Parkinson's From Decision-making to Daily Life with the Device."

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) today launches "Deep Brain Stimulation and Parkinson's From Decision-making to Daily Life with the Device."
  • And ultimately to empower people and families to learn more, ask questions, or start conversations about this treatment option."
  • "Deep Brain Stimulation and Parkinson's From Decision-making to Daily Life with the Device" was made possible through support from Abbott Laboratories.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.

CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

Retrieved on: 
Tuesday, March 9, 2021
Parkinson's disease, Geriatrics, Psychiatric diagnosis, Medical specialties, Branches of biology, Parkinson, Clinical medicine, Parkinson's disease clinical research

Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment

Key Points: 
  • Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
    With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinsons disease ever performed
    CAMBRIDGE, Mass.
  • Including more than 120 study sites around the world, CENTOGENE is leading the largest study of its kind a global observational study focusing on the role of genetics in Parkinson's disease (PD).
  • Prof. Peter Bauer, Chief Genomic Officer at CENTOGENE, said, "We are pleased to have reached such a pivotal point in our Parkinsons disease study.
  • The Rostock International Parkinson's Disease Study (ROPAD) is a global epidemiological study focusing on the role of genetics in Parkinson's disease (PD).

Parkinson's Foundation Adds University of Miami Miller School of Medicine to PD GENEration Research Study

Retrieved on: 
Tuesday, March 2, 2021
Branches of biology, Medicine, Parkinson's disease, Clinical medicine, Medical genetics, Parkinson's Foundation, Neurology, Genetic testing, Parkinson's disease clinical research, Alice Lazzarini

Genetic testing and counseling through PD GENEration are available in English and Spanish both in-person at the university's medical school and online.

Key Points: 
  • Genetic testing and counseling through PD GENEration are available in English and Spanish both in-person at the university's medical school and online.
  • "This program will help people with PD better understand their diagnosis while improving Parkinson's care by accelerating and supporting research."
  • Scientists will use the genetic testing results obtained through this study for future research to develop improved treatments and personalized medicine for Parkinson's.
  • The study is led by Dr. Carlos Singer, MD, Professor of Neurology and FoundingDirector of the Parkinson's Foundation Center of Excellence at the University of Miami Miller School of Medicine.

Newronika Announces First Patient Implanted with AlphaDBSTM Closed-loop Adaptive Deep Brain Stimulation System

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Medicine, Clinical medicine, Neurotechnology, Neuroprosthetics, Electrotherapy, Medical devices, Deep brain stimulation, Tourette syndrome, Parkinson's disease, Neuromodulation, Parkinson's disease clinical research

Newronika has initiated a multi-center clinical trial to evaluate the AlphaDBS adaptive closed-loop system in patients with Parkinson's disease.

Key Points: 
  • Newronika has initiated a multi-center clinical trial to evaluate the AlphaDBS adaptive closed-loop system in patients with Parkinson's disease.
  • The neuronal activity recorded in the first patient with Parkinson's disease from the fully implanted system confirms the intended performance of the AlphaDBS System.
  • The data collected using the implanted system corroborate previous findings from studies of 48 patients using an external system in three different investigational clinical trials.
  • AlphaDBS is a unique deep brain stimulation system that continuously records and interprets bioelectrical neuronal activity in the brain where stimulation is delivered.

Eye Exam Could Lead to Early Parkinson's Disease Diagnosis

Retrieved on: 
Monday, November 23, 2020
Neurological disorders, Branches of biology, Neurodegenerative disorders, Aging-associated diseases, Geriatrics, Psychiatric diagnosis, Parkinson's disease, Tremor, Central nervous system disease, Medical diagnosis, Sepiapterin reductase deficiency, Parkinson's disease clinical research

Diagnosis is typically based on symptoms like tremors, muscle stiffness and impaired balancean approach that has significant limitations.

Key Points: 
  • Diagnosis is typically based on symptoms like tremors, muscle stiffness and impaired balancean approach that has significant limitations.
  • These characteristics present an opportunity to leverage the power of AI to examine images of the eyes for signs of Parkinson's disease.
  • Using pictures of the back of the eye from both patients with Parkinson's disease and control participants, they trained the SVM to detect signs on the images suggestive of disease.
  • "The single most important finding of this study was that a brain disease was diagnosed with a basic picture of the eye," Diaz said.

CISCRP Honors "Medical Heroes," Participants in Clinical Trials

Retrieved on: 
Friday, October 23, 2020
Health sciences, Health, Clinical research, Medical research, Clinical trials, Pharmaceutical industry, Design of experiments, Parkinson's disease clinical research, Patient recruitment

Study participants and researchers focused on clinical research experiences and misconceptions, health advocacy and equity, and how the pandemic has impacted clinical trials.

Key Points: 
  • Study participants and researchers focused on clinical research experiences and misconceptions, health advocacy and equity, and how the pandemic has impacted clinical trials.
  • Anyone interested in learning more about participating in clinical trials can obtain information from CISCRP at 1-877-MED-HERO or http://www.ciscrp.org .
  • CISCRP offers a free service designed to help patients and caregivers find clinical trials within their medical condition and location at http://www.searchclinicaltrials.org .
  • The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process.

Parkinson's Foundation Expands PD GENEration Research Study to Include Genetic Testing and Counseling At-Home and in English and Spanish

Retrieved on: 
Tuesday, September 29, 2020
Parkinson's disease, Medicine, Clinical medicine, Medical specialties, Parkinson's Foundation, Genetic testing, Parkinson's disease clinical research, The Michael J. Fox Foundation

MIAMIand NEW YORK, Sept. 29, 2020 /PRNewswire/ --The Parkinson's Foundation today announced that it has expanded PD GENEration: Mapping the Future of Parkinson's Disease to include at-home genetic testing and counseling in English and Spanish for people with Parkinson's disease (PD) at no cost.

Key Points: 
  • MIAMIand NEW YORK, Sept. 29, 2020 /PRNewswire/ --The Parkinson's Foundation today announced that it has expanded PD GENEration: Mapping the Future of Parkinson's Disease to include at-home genetic testing and counseling in English and Spanish for people with Parkinson's disease (PD) at no cost.
  • PD GENEration is the first national Parkinson's study to offer bilingual genetic testing at-home or in a clinical setting with counseling.
  • Scientists will use the genetic testing results obtained through this study for future research to develop improved treatments and personalized medicine for Parkinson's.
  • Offering PD GENEration testing at home and in Spanish removes barriers, making it easier for the Hispanic community to participate in Parkinson's research.

Deep Brain Stimulation In Parkinson's Disease Market Worth $1.42 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Monday, August 3, 2020
Medicine, Clinical medicine, Medical specialties, Neurotechnology, Neurosurgical procedures, Electrotherapy, Medical devices, Parkinson's disease, Deep brain stimulation, Levodopa-induced dyskinesia, Parkinson's disease clinical research

Surge in the incidence of Parkinson's Disease (PD) and growing awareness about the deep brain stimulation in PD are driving the market.

Key Points: 
  • Surge in the incidence of Parkinson's Disease (PD) and growing awareness about the deep brain stimulation in PD are driving the market.
  • Rising prevalence of Parkinson's disease has raised the demand for deep brain stimulators as an alternative therapy.
  • Deep brain stimulation has been proved to play an important role in providing therapeutic solutions for the symptoms of Parkinson's disease, which is expected to fuel the market growth during the forecast period.
  • Grand View Research has segmented the global DBS in Parkinson's disease market on the basis of product, end use, and region:
    DBS In Parkinson's Disease Product Outlook (Revenue, USD Million, 2016 - 2028)
    DBS In Parkinson's Disease End-use Outlook (Revenue, USD Million, 2016 - 2028)

Deep Brain Stimulation In Parkinson's Disease Market Worth $1.42 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Monday, August 3, 2020
Medicine, Clinical medicine, Medical specialties, Neurotechnology, Neurosurgical procedures, Electrotherapy, Medical devices, Parkinson's disease, Deep brain stimulation, Levodopa-induced dyskinesia, Parkinson's disease clinical research

Surge in the incidence of Parkinson's Disease (PD) and growing awareness about the deep brain stimulation in PD are driving the market.

Key Points: 
  • Surge in the incidence of Parkinson's Disease (PD) and growing awareness about the deep brain stimulation in PD are driving the market.
  • Rising prevalence of Parkinson's disease has raised the demand for deep brain stimulators as an alternative therapy.
  • Deep brain stimulation has been proved to play an important role in providing therapeutic solutions for the symptoms of Parkinson's disease, which is expected to fuel the market growth during the forecast period.
  • Grand View Research has segmented the global DBS in Parkinson's disease market on the basis of product, end use, and region:
    DBS In Parkinson's Disease Product Outlook (Revenue, USD Million, 2016 - 2028)
    DBS In Parkinson's Disease End-use Outlook (Revenue, USD Million, 2016 - 2028)